Patent ID: 8809528

Claim:
A method for modulating vanilloid receptor 1 activity, comprising administering to a mammal in need thereof a therapeutically effective amount of a quinazolinone compound of the formula (Ia) wherein R 1 is C 2 -C 6 alkyl, (C 1 -C 6 alkyl)C 1 -C 6 alkyl, di-(C 1 -C 6 alkyl)C 1 -C 6 alkyl, or C 3 -C 6 cycloalkyl; each R 2 , independently, is halogen, C 1 -C 6 alkyl, halogen-substituted C 1 -C 6 alkyl, hydroxyC 1 -C 6 alkyl, cyano or a group —C(═O)—R 2a , where R 2a is C 1 -C 6 alkyl; R 3 is hydrogen, halogen, C 1 -C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, hydroxy, hydroxy-substituted C 1 -C 6 alkyl, C 1 -C 6 alkoxy, C 3 -C 6 cycloalkyl, cyano, —C(C═O)H, phenyl, (C 3 -C 6 cycloalkyl)C 1 -C 6 alkoxy, (C 1 -C 6 alkoxycarbonylamino)C 1 -C 6 alkoxy or (C 1 -C 6 alkylcarbonylamino)C 1 -C 6 alkoxy; R 4 is hydroxy, esterified hydroxy, etherified hydroxy, a group or a group where R 4a is halogen-substituted C 1 -C 6 alkyl, or a group where R 4b is benzyl or phenylethyl; and m is 1 or 2, in free base form or in pharmaceutically acceptable salt form.